Cargando…
MEK1/2 as a Therapeutic Target in Sickle Cell Disease
Identification of novel therapeutic targets has improved diagnostics and treatment of many diseases. Many innovative treatment strategies have been developed based on the newly identified biomarkers and key molecules. Most of the research focused on ways to manipulate signaling pathways by activatin...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839713/ https://www.ncbi.nlm.nih.gov/pubmed/31709379 http://dx.doi.org/10.23937/2469-5696/1410038 |
_version_ | 1783467481718849536 |
---|---|
author | Zennadi, Rahima |
author_facet | Zennadi, Rahima |
author_sort | Zennadi, Rahima |
collection | PubMed |
description | Identification of novel therapeutic targets has improved diagnostics and treatment of many diseases. Many innovative treatment strategies have been developed based on the newly identified biomarkers and key molecules. Most of the research focused on ways to manipulate signaling pathways by activating or suppressing them, validate new therapeutic targets for treatment, and epigenetic treatment of diseases. With the identification of aberrations in multiple growth pathways, the focus then shifted to the small molecules involved in these pathways for targeted therapy. In this communication/short review, we highlight the importance of identification of abnormal activation of the mitogen-activated protein kinase (MAPK), ERK1/2, and its upstream mediator MEK1/2, in erythrocytes in patients with sickle cell disease (SCD) critical for the adhesive interactions of these cells with the endothelium, and leukocytes promoting circulatory obstruction leading to tissue ischemia and infraction. We also discuss how targeting this signaling cascade with MEK1/2 inhibitors can reverse acute vasoocclusive crises in SCD. |
format | Online Article Text |
id | pubmed-6839713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-68397132019-11-08 MEK1/2 as a Therapeutic Target in Sickle Cell Disease Zennadi, Rahima Int J Blood Res Disord Article Identification of novel therapeutic targets has improved diagnostics and treatment of many diseases. Many innovative treatment strategies have been developed based on the newly identified biomarkers and key molecules. Most of the research focused on ways to manipulate signaling pathways by activating or suppressing them, validate new therapeutic targets for treatment, and epigenetic treatment of diseases. With the identification of aberrations in multiple growth pathways, the focus then shifted to the small molecules involved in these pathways for targeted therapy. In this communication/short review, we highlight the importance of identification of abnormal activation of the mitogen-activated protein kinase (MAPK), ERK1/2, and its upstream mediator MEK1/2, in erythrocytes in patients with sickle cell disease (SCD) critical for the adhesive interactions of these cells with the endothelium, and leukocytes promoting circulatory obstruction leading to tissue ischemia and infraction. We also discuss how targeting this signaling cascade with MEK1/2 inhibitors can reverse acute vasoocclusive crises in SCD. 2019-04-04 2019 /pmc/articles/PMC6839713/ /pubmed/31709379 http://dx.doi.org/10.23937/2469-5696/1410038 Text en http://creativecommons.org/licenses/by-nc/4.0// This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Zennadi, Rahima MEK1/2 as a Therapeutic Target in Sickle Cell Disease |
title | MEK1/2 as a Therapeutic Target in Sickle Cell Disease |
title_full | MEK1/2 as a Therapeutic Target in Sickle Cell Disease |
title_fullStr | MEK1/2 as a Therapeutic Target in Sickle Cell Disease |
title_full_unstemmed | MEK1/2 as a Therapeutic Target in Sickle Cell Disease |
title_short | MEK1/2 as a Therapeutic Target in Sickle Cell Disease |
title_sort | mek1/2 as a therapeutic target in sickle cell disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839713/ https://www.ncbi.nlm.nih.gov/pubmed/31709379 http://dx.doi.org/10.23937/2469-5696/1410038 |
work_keys_str_mv | AT zennadirahima mek12asatherapeutictargetinsicklecelldisease |